Monte Rosa Therapeutics (GLUE) Cash from Investing Activities Growth (1y) (2021 - 2026)
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) Cash from Investing Activities Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -41.67% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -157.08% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 26.37% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -89.24% |
| 10 | Monte Rosa Therapeutics | 1.40 Bn | 771.57 Mn | - | -213.96% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -213.96% |
| Mar 31, 2026 | -160.40% |
| Dec 31, 2025 | -110.60% |
| Sep 30, 2025 | 1.03% |
| Jun 30, 2025 | 141.41% |
| Mar 31, 2025 | -1,117.24% |
| Dec 31, 2024 | -316.10% |
| Sep 30, 2024 | 5.95% |
| Jun 30, 2024 | -429.69% |
| Mar 31, 2024 | -51.53% |
| Dec 31, 2023 | 126.51% |
| Sep 30, 2023 | 20.82% |
| Jun 30, 2023 | 230.18% |
| Mar 31, 2023 | 111.26% |
| Dec 31, 2022 | -1,670.23% |
| Sep 30, 2022 | 1,846.98% |
| Jun 30, 2022 | -427.55% |
| Mar 31, 2022 | -8,042.53% |
| Dec 31, 2021 | -156.91% |
| Sep 30, 2021 | -81.51% |